Journal: Journal of cellular physiology

Article Title: CF102 an A 3 Adenosine Receptor Agonist Mediates Anti-Tumor and Anti-Inflammatory Effects in the Liver

doi: 10.1002/jcp.22593

Figure Lengend Snippet: Effect of CF102 on the development of Con. A-induced hepatitis in mice. Acute hepatitis was induced in mice by I.V. injection of Con.A. CF102 (100 μg/kg) was administered orally twice daily, starting 8 h after Con. A injection. Serum levels of liver enzymes were measured 21 h after Con. A injection. CF102 markedly decreased SGOT and SGPT levels in comparison to the vehicle-treated group (P < 0.05).

Article Snippet: Reagents The A 3 AR agonist CF102 (2-chloro- N 6 -(3-iodobenzyl)-adenosine-5′- N -methyl-uronamide, also known as Cl-IB-MECA), was synthesized for Can-Fite BioPharma by Albany Molecular Research, Inc., Albany, NY.

Techniques: Injection, Comparison

Journal: Journal of cellular physiology

Article Title: CF102 an A 3 Adenosine Receptor Agonist Mediates Anti-Tumor and Anti-Inflammatory Effects in the Liver

doi: 10.1002/jcp.22593

Figure Lengend Snippet: CF102 protected the liver tissue from Con. A-induced damage. Acute hepatitis was induced in mice by I.V. injection of Con.A. Tissue sections of the livers were withdrawn from the mice 21 h after Con. A injection, fixed in formalin and subjected to H&E staining. In the vehicle-treated group, an extensive area of necrosis was observed while in the CF102-treated group no sign of necrosis was noted.

Article Snippet: Reagents The A 3 AR agonist CF102 (2-chloro- N 6 -(3-iodobenzyl)-adenosine-5′- N -methyl-uronamide, also known as Cl-IB-MECA), was synthesized for Can-Fite BioPharma by Albany Molecular Research, Inc., Albany, NY.

Techniques: Injection, Staining

Journal: Journal of cellular physiology

Article Title: CF102 an A 3 Adenosine Receptor Agonist Mediates Anti-Tumor and Anti-Inflammatory Effects in the Liver

doi: 10.1002/jcp.22593

Figure Lengend Snippet: CF102 acted as an anti-inflammatory agent in Con. A-induced hepatitis. Acute hepatitis was induced in mice by I.V. injection of Con.A. Liver tissues were collected 21 h later and protein extracts were derived from naïve- and Con. A-induced hepatitis mice were subjected to WB analysis. CF102 treatment induced (A) down-regulation in the expression levels of phosphorylated GSK-3β while the total GSK-3β expression levels remained almost unchanged in comparison to the vehicle-treated group. B: Down-regulation in the expression levels of the pro-inflammatory proteins NF-κB and TNF-α in comparison to the vehicle-treated group P < 0.05).

Article Snippet: Reagents The A 3 AR agonist CF102 (2-chloro- N 6 -(3-iodobenzyl)-adenosine-5′- N -methyl-uronamide, also known as Cl-IB-MECA), was synthesized for Can-Fite BioPharma by Albany Molecular Research, Inc., Albany, NY.

Techniques: Injection, Derivative Assay, Expressing, Comparison

Journal: Journal of cellular physiology

Article Title: CF102 an A 3 Adenosine Receptor Agonist Mediates Anti-Tumor and Anti-Inflammatory Effects in the Liver

doi: 10.1002/jcp.22593

Figure Lengend Snippet: CF102 prevented apoptosis in the liver upon Con. A-induced hepatitis. Acute hepatitis was induced in mice by I.V. injection of Con.A. Liver tissue was collected 21 h later and protein extracts from derived from naïve- and Con. A-induced hepatitis mice were subjected to WB analysis. CF102 treatment induced down-regulation in the pro-apoptotic proteins FasR, Bax, and Bad in comparison to the vehicle-treated group (P = 0.05).

Article Snippet: Reagents The A 3 AR agonist CF102 (2-chloro- N 6 -(3-iodobenzyl)-adenosine-5′- N -methyl-uronamide, also known as Cl-IB-MECA), was synthesized for Can-Fite BioPharma by Albany Molecular Research, Inc., Albany, NY.

Techniques: Injection, Derivative Assay, Comparison

Journal: Journal of cellular physiology

Article Title: CF102 an A 3 Adenosine Receptor Agonist Mediates Anti-Tumor and Anti-Inflammatory Effects in the Liver

doi: 10.1002/jcp.22593

Figure Lengend Snippet: CF102 inhibits the proliferation of human HCC Hep-3B cells. Hep-3B cells were incubated for 48 h with CF102 at concentrations of 1 and 10 nM. 3[H]-thymidine incorporation assay revealed that CF102 inhibited linearly the proliferation of the Hep-3B cells.

Article Snippet: Reagents The A 3 AR agonist CF102 (2-chloro- N 6 -(3-iodobenzyl)-adenosine-5′- N -methyl-uronamide, also known as Cl-IB-MECA), was synthesized for Can-Fite BioPharma by Albany Molecular Research, Inc., Albany, NY.

Techniques: Incubation, Thymidine Incorporation Assay

Journal: Journal of cellular physiology

Article Title: CF102 an A 3 Adenosine Receptor Agonist Mediates Anti-Tumor and Anti-Inflammatory Effects in the Liver

doi: 10.1002/jcp.22593

Figure Lengend Snippet: Modulation of A3AR expression levels in Hep-3B treated with CF102. Hep-3B cells were incubated for 48 h with CF102 at a concentration of 10 nM. Protein extracts derived from the Hep-3B cells were subjected to WB analysis. CF102 treatment resulted in down-regulation of A3AR expression levels.

Article Snippet: Reagents The A 3 AR agonist CF102 (2-chloro- N 6 -(3-iodobenzyl)-adenosine-5′- N -methyl-uronamide, also known as Cl-IB-MECA), was synthesized for Can-Fite BioPharma by Albany Molecular Research, Inc., Albany, NY.

Techniques: Expressing, Incubation, Concentration Assay, Derivative Assay

Journal: Journal of cellular physiology

Article Title: CF102 an A 3 Adenosine Receptor Agonist Mediates Anti-Tumor and Anti-Inflammatory Effects in the Liver

doi: 10.1002/jcp.22593

Figure Lengend Snippet: Modulation of down-stream signaling proteins expression levels in Hep-3B treated with CF102. Hep-3B cells were incubated for 48 h with CF102 at a concentration of 10 nM. Protein extracts derived from the Hep-3B cells were subjected to WB analysis. CF102 treatment induced down-regulation of PI3K, PKB/Akt, and NF-κB expression levels and increased the expression levels of the pro-apoptotic protein caspase-3.

Article Snippet: Reagents The A 3 AR agonist CF102 (2-chloro- N 6 -(3-iodobenzyl)-adenosine-5′- N -methyl-uronamide, also known as Cl-IB-MECA), was synthesized for Can-Fite BioPharma by Albany Molecular Research, Inc., Albany, NY.

Techniques: Expressing, Incubation, Concentration Assay, Derivative Assay

Journal: Journal of cellular physiology

Article Title: CF102 an A 3 Adenosine Receptor Agonist Mediates Anti-Tumor and Anti-Inflammatory Effects in the Liver

doi: 10.1002/jcp.22593

Figure Lengend Snippet: CF102 inhibited the development of Hep-3B tumors in a xenograft model. Hep-3B cells were injected subcutaneously into the flank of balb/c nude mice. Oral treatment with CF102 (100 μg/kg, three times per day) was initiated when the tumor reached ~50–100 mm3 in size and lasted until study termination. A: CF102 treatment inhibited tumor growth in comparison to the vehicle-treated group. B,C: At the end of the study an inhibition of 46% in tumor volume was observed in the CF102-treated group (P < 0.05).

Article Snippet: Reagents The A 3 AR agonist CF102 (2-chloro- N 6 -(3-iodobenzyl)-adenosine-5′- N -methyl-uronamide, also known as Cl-IB-MECA), was synthesized for Can-Fite BioPharma by Albany Molecular Research, Inc., Albany, NY.

Techniques: Injection, Comparison, Inhibition

Journal: Journal of cellular physiology

Article Title: CF102 an A 3 Adenosine Receptor Agonist Mediates Anti-Tumor and Anti-Inflammatory Effects in the Liver

doi: 10.1002/jcp.22593

Figure Lengend Snippet: CF102 up-regulated the apoptotic pathway in Hep-3B tumor cells. Hep-3B cells were injected subcutaneously into the flank of Balb/c nude mice. Oral treatment with CF102 (100 μg/kg, three times per day) was initiated when the tumor reached ~50–100 mm3 in size and lasted until study termination. Upon study termination, the tumors were excised and subjected to WB analysis. CF102 treatment induced up-regulation in the expression levels the pro-apoptotic proteins FasR, caspase-8, Bax, Bad, cytochrome-c, and caspase-3 in comparison to the vehicle-treated group (P = 0.05).

Article Snippet: Reagents The A 3 AR agonist CF102 (2-chloro- N 6 -(3-iodobenzyl)-adenosine-5′- N -methyl-uronamide, also known as Cl-IB-MECA), was synthesized for Can-Fite BioPharma by Albany Molecular Research, Inc., Albany, NY.

Techniques: Injection, Expressing, Comparison

Journal: Frontiers in Pharmacology

Article Title: Adenosine Metabotropic Receptors in Chronic Pain Management

doi: 10.3389/fphar.2021.651038

Figure Lengend Snippet: The figure illustrates the several A3AR agonists use in different preclinical model of neuropathic pain of various origins.

Article Snippet: DS is founder of BioIntervene, Inc., a company developing A3AR agonists for clinical use.

Techniques: